How many acquisitions has Gilead made so far?

Gilead has completed 21 acquisitions so far, with an average acquisition amount of $3.33B.

Which countries does Gilead usually acquire in?

Gilead has made acquisitions in 5 countries with the most activity in United States and Germany.

Which sectors does Gilead target for acquisitions?

Most of Gilead's acquisitions are in Oncology (14) and Immunotherapy (8).

List of 21 Acquisitions by Gilead (May 2026)

Q: Which is Gilead's latest acquisition?

Gilead's most recent acquisition is Tubulis Technologies, a Developer of antibody-drug conjugates for the treatment of cancer, acquired in April 2026 for $3.15B.

Most viewed in 2019

Gilead has completed a total of 21 acquisitions. These acquisitions span 11 distinct sectors, notably Oncology (14), Immunotherapy (8), and Infectious Diseases (3). They occurred across 5 countries, including the United States (16), Germany (2), and the United Kingdom (1). Peak acquisition years were 2026 (3), 2020 (3), and 2017 (2). Over the last five years, from 2020 to 2025, the average number of acquisitions per year was 0.6. So far in the current calendar year, 3 acquisitions have been completed. The most recent acquisition was Tubulis Technologies, a developer of antibody-drug conjugates for the treatment of cancer. Founded in 2015 and located in Munich, it was acquired in April 2026 for $3.15B.

Here's the year on year acquisition history of Gilead:

Number of Total Acquisitions

Year	# Acquisitions
2026	3
2024	1
2023	1
2022	1
2020	3
2017	2
2015	1
2012	1
2011	2
2010	2
2009	1
2006	2
2002	1

View all Acquisitions by Gilead

Recent acquisitions by Gilead

Gilead's most recent acquisition - Tubulis Technologies is a Developer of antibody-drug conjugates for the treatment of cancer, founded in 2015 and located in Munich. Gilead acquired it in April 2026 for a price of $*****.

Here is the list of all acquisitions by Gilead sorted by the latest acquisition date:

Acquired on	Acquired Company	Acquisition Price	Facilitators	Stake Acquired	Acquisition Multiple
Apr 07, 2026	Tubulis Technologies	yetd	xr{y	93	303
Mar 23, 2026	Ouro Medicines	nby{	xeqh	98	337
Feb 23, 2026	Arcellx	lvmv	{bro	98	582
Feb 12, 2024	CymaBay Therapeutics	pgdj	ggin	53	192
May 01, 2023	XinThera	yfsl	fmil	21	811